Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA non-small cell lung cancer and stage III colon cancer MRD testing helps clinicians track a patient's risk ...

Molecular residual disease (MRD) testing detects cancer recurrence months before traditional imaging Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA ...

(RTTNews) - Labcorp (LH) Wednesday has announced a significant expansion of its precision oncology offerings with two advanced diagnostic solutions to improve cancer detection and treatment decisions.

Colorectal cancer continues to be one of the leading causes of cancer-related deaths worldwide. However, recent advancements in medical screening have brought new hope in the fight against this deadly ...

BURLINGTON, N.C. - Labcorp (NYSE:LH) announced Tuesday it has expanded its molecular residual disease (MRD) testing portfolio to help clinicians detect cancer recurrence earlier than traditional ...

Earlier this week, Labcorp Holdings Inc. declared a quarterly cash dividend of US$0.72 per share, payable on March 12, 2026 to shareholders of record as of February 27, 2026. In parallel, Labcorp ...